Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Phillip A. Geter"'
Autor:
Elizabeth Sassani, Beatrix Ueberheide, Linda Clijsters, John F. Dankert, David Fenyö, Michele Pagano, Phillip A. Geter, Keria Bermudez-Hernandez, Gergely Róna, Jeffrey R. Skaar, Robert J. Schneider
Publikováno v:
Molecular Cell. 64:507-519
SLBP (stem-loop binding protein) is a highly conserved factor necessary for the processing, translation, and degradation of H2AFX and canonical histone mRNAs. We identified the F-box protein cyclin F, a substrate recognition subunit of an SCF (Skp1-C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b855278c645364b718ee39b60c85826a
https://doi.org/10.1016/j.molcel.2016.09.010
https://doi.org/10.1016/j.molcel.2016.09.010
Autor:
Rezina Arju, Abhilash Gadi, Amandine Alard, Sofia Bakogianni, Shah Giashuddin, Phillip A. Geter, Jacqueline Bromberg, Robert J. Schneider, Amanda Ernlund
Publikováno v:
Genesdevelopment. 31(22)
The majority of breast cancers expresses the estrogen receptor (ER+) and is treated with anti-estrogen therapies, particularly tamoxifen in premenopausal women. However, tamoxifen resistance is responsible for a large proportion of breast cancer deat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1af044fb12a07a876cbf79e2a2ebabe
https://pubmed.ncbi.nlm.nih.gov/29269484
https://pubmed.ncbi.nlm.nih.gov/29269484
Autor:
Phillip A. Geter, Robert J. Schneider
Publikováno v:
Cancer Research. 77:B33-B33
Currently, ER+ breast cancer is treated with adjuvant antiestrogen therapies (i.e. tamoxifen and raloxifene). Despite maintaining expression of the estrogen receptor, many women treated with adjuvant therapy develop resistance several years after cur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9635b0bbd85d178290864e39e16a5e16
https://doi.org/10.1158/1538-7445.transcontrol16-b33
https://doi.org/10.1158/1538-7445.transcontrol16-b33